BioTech

STAT Plus: Lilly to accumulate Dermira for $1.1 billion, including eczema drug to its pipeline

Eli Lilly mentioned Friday that it’ll purchase Dermira, a small biotech creating medication for power pores and skin situations, for $1.1 billion.

The centerpiece of the deal is the Dermira drug known as lebrikizumab that goals to deal with folks affected by moderate-to-severe atopic dermatitis, the commonest type of eczema, a illness characterised by infected, itchy, and scaly pores and skin.

Proceed to STAT Plus to learn the total story…

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker